Picture of Alcon AG logo

ALC — Alcon AG News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth

Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth


Overview

  • Switzerland's eye care company Q3 sales rose 5% yr/yr, a slight miss versus analyst expectations

  • Core diluted EPS for Q3 beat analyst expectations

  • Growth driven by innovation and new products, offset by U.S. implantables competition


Outlook

  • Alcon expects 2026 net sales growth of about 6% in constant currency

  • Company forecasts 2026 core operating margin to rise 100-150 basis points vs prior year

  • Alcon projects 2026 core diluted EPS growth of 12% to 14% in constant currency


Result Drivers

  • CONSUMABLES AND PROCEDURAL VOLUMES - Co said higher surgical consumables sales were driven by increased procedural volumes and price increases

  • PREMIUM PRODUCTS AND PRICE INCREASES - Co said Vision Care growth was led by premium contact lenses and price increases, especially in the U.S.

  • INTERNATIONAL MARKETS AND NEW PRODUCTS - Co said international markets and new products like PanOptix Pro helped offset U.S. implantables decline


Company press release: ID:nBw8xVDnPa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Miss*

$2.72 bln

$2.74 bln (14 Analysts)

Q3 Core Diluted EPS

Beat

$0.91

$0.87 (13 Analysts)

Q3 EPS

$0.54

Q3 Core Operating Margin

21.80%

Q3 Operating Margin

14.00%

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Alcon AG is CHF77.35, about 25% above its November 10 closing price of CHF61.88

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Nov 10 - Legend Biotech Q3 revenue rises slightly less than expected

  • Nov 9 - Annexon Biosciences Q3 net loss narrows on lower R&D expenses, cash runway extends to 2028

  • Nov 10 - Watches of Switzerland lifts outlook floor as US, UK demand remains strong


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Alcon AG

See all news